Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miracor Medical Systems GMBH

This article was originally published in Start Up

Executive Summary

Miracor Medical Systems aims to improve post-PCI myocardial infusion to repair the damage caused by heart attacks. The company has developed minimally invasive technology to intermittently occlude the coronary sinus to block venous outflow from the heart. The resulting rise in pressure redistributes blood in the myocardium, where Miracor believes it will regenerate damaged tissue and lead to improved outcomes for patients.
Advertisement

Related Content

Market Intel: Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions
Start-Up Previews (10/2009)
Start-Up Previews (10/2009)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT037627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel